Pts with stage IIB-IIIB, wildtype EGFR/ALK NSCLC, ECOG PS 0-1 were eligible. All pts received 2-4 cycles of toripalimab (240mg, q3w) plus double platinum-based chemotherapy….42 pts (42/65, 64.6%) achieved MPR, including 31 pts (31/65, 47.7%) with pCR. 62 pts received 2 or 3 cycles of treatment, and no significant difference in MPR or pCR rate was observed between 2 and 3 cycles of treatment (32/48, 66.7% vs 8/14, 57.1%, p=0.512; 25/48, 52.1% vs 5/14, 35.7%, p=0.281). After 2 cycles of treatment, the primary tumor shranked significantly with a -40% (IQR: -100%, +25%) median regression rate, and tended to flatten with a -4.63% (IQR: -21.54%, +21.15%) median regression rate after another 1-2 cycles....Neoadjuvant toripalimab and chemotherapy is a promising treatment for pts with stage IIB-IIIB NSCLC.

Study eligibility involved stage IIB-IIIB, wildtype EGFR/ALK NSCLC pts....Pts received 2-4 cycles of toripalimab (240mg, q3w) plus cisplatin-based chemotherapy...1 had partial response (PR) after neoadjuvant treatment and maintained stable disease (SD) after 10 months of observation, another had clinical complete response (cCR) after neoadjuvant treatment.... Neoadjuvant toripalimab plus platinum-based doublet is a promising, tolerable and effective treatment for pts with stage IIB-IIIB NSCLC.

Study eligibility involved stage IIB-IIIB, wildtype EGFR/ALK NSCLC...Pts received 2-4 cycles of toripalimab (240mg, q3w) plus cisplatin-based chemotherapy….20 pts (20/32, 62.5%) achieved MPR, including 16 pts (16/32, 50%) with pCR. 6 pts (6/8, 75%), 12 pts (12/18, 66.7%), and 2 pts (2/6, 33.3%) with stage IIB, IIIA and IIIB achieved MPR respectively....Toripalimab plus platinum-based doublet as neoadjuvant treatment yields a high MPR rate...